Milestone Pharmaceuticals (MIST) Total Current Liabilities (2018 - 2026)
Milestone Pharmaceuticals' (MIST) quarterly Total Current Liabilities came in at $20.9 million in Q1 2026, up 61.57% YoY from $13.0 million in Q1 2025, and up 49.82% on a QoQ basis from $14.0 million in Q4 2025.
Milestone Pharmaceuticals (MIST) Total Current Liabilities (2018 - 2026) Analysis & Trends
Milestone Pharmaceuticals (MIST) has 9 years of Total Current Liabilities data on file, last reported at $20.9 million in Q1 2026.
- Quarterly Total Current Liabilities rose 61.57% year-over-year to $20.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.9 million (up 61.57% YoY) and the FY2025 annual result came in at $14.0 million, up 72.03% from the prior year.
- Total Current Liabilities grew to $20.9 million in Q1 2026, from $14.0 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $20.9 million in Q1 2026 to a low of $4.1 million in Q1 2024.
- A 5-year average of $8.3 million and a median of $7.2 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities tumbled 48.14% — and 2025, when it surged 213.87%.
- Tracing MIST's Total Current Liabilities over 5 years: stood at $6.1 million in 2022, then gained by 17.71% to $7.2 million in 2023, then climbed by 12.46% to $8.1 million in 2024, then surged by 72.03% to $14.0 million in 2025, then soared by 49.82% to $20.9 million in 2026.
- The last three Total Current Liabilities figures came in at $20.9 million (Q1 2026), $14.0 million (Q4 2025), and $10.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 630.93 Mn |
| 10 | Milestone Pharmaceuticals | 42.91 Mn | -128.59 Mn | - | 22.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.18 Mn |
| Mar 31, 2026 | 20.94 Mn |
| Dec 31, 2025 | 13.98 Mn |
| Sep 30, 2025 | 10.52 Mn |
| Jun 30, 2025 | 9.28 Mn |
| Mar 31, 2025 | 12.96 Mn |
| Dec 31, 2024 | 8.13 Mn |
| Sep 30, 2024 | 5.26 Mn |
| Jun 30, 2024 | 4.57 Mn |
| Mar 31, 2024 | 4.13 Mn |
| Dec 31, 2023 | 7.23 Mn |
| Sep 30, 2023 | 8.11 Mn |
| Jun 30, 2023 | 6.81 Mn |
| Mar 31, 2023 | 7.96 Mn |
| Dec 31, 2022 | 6.14 Mn |
| Sep 30, 2022 | 6.52 Mn |
| Jun 30, 2022 | 4.26 Mn |
| Mar 31, 2022 | 4.61 Mn |
| Dec 31, 2021 | 6.78 Mn |
| Sep 30, 2021 | 5.85 Mn |